SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

405

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

September 30, 2024

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

SCT-I10A

Participants receive SCT-I10A intravenously，200mg，d1，Q3w

DRUG

SCT510

Participants receive SCT510 intravenously，15mg/kg，d1，Q3w

DRUG

Sorafenib 200mg

Participants receive sorafenib orally，400mg bid

Trial Locations (1)

307 Hospital of PLA, Beijing

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY